ProCE Banner Activity

Managing Patients With HER2+ Breast Cancer and Brain Metastasis: Slides

Slideset

Download these expert-selected slides on optimal treatment of patients with HER2-positive breast cancer with brain metastases.

Released: February 02, 2021

Expiration: February 01, 2022

Share

Provided by

Provided by the National Comprehensive Cancer Network in collaboration with Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

Genentech, a member of the Roche Group

Puma Biotechnology, Inc.

Faculty Disclosure

Primary Author

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Associate Director, Susan F. Smith Center for Women’s Cancers
Senior Physician, Dana-Farber Cancer Institute
Associate Professor of Medicine, Harvard Medical School
Boston, Massachusetts

Sara M. Tolaney, MD, MPH: consultant/advisor/speaker: Aadi Bio, Artios, Arvinas, AstraZeneca, Bayer, BeiGene, Bicycle, BioNTech, Blueprint Medicines, Bristol Myers Squibb/SystImmune, Circle, Cullinan, Daiichi Sankyo, eFFECTOR, Eisai, Genentech/Roche, Gilead, Hengrui, Incyte, Jazz, Johnson & Johnson/Ambrx, Launch Therapeutics, Lilly, Menarini/Stemline, Merck, Mersana, Natera, Novartis, Pfizer, Reveal Genomics, Sanofi, Seattle Genetics, Sumitovant, Summit Therapeutics, Tango, Umoja Biopharma, Zentalis, Zuellig, Zymeworks; researcher (paid to institution): AstraZeneca, Bristol Myers Squibb/SystImmune, Cyclacel, Eisai, Exelixis, Genentech/Roche, Gilead, Jazz, Lilly, Menarini/Stemline, Merck, Nanostring, Novartis, OncoPep, Pfizer/Seattle Genetics.